loader
Please Wait
Applying Filters...

Others: Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239 - Aptose Biosciences

Xls
Menu